Triple Combination Therapy: A Promising Path Forward against β-Lactamase-Mediated Resistance
Journal of Medicinal Chemistry · 22.10.2026 · 69 (20) · 23075-23091
DOI: 10.1021/acs.jmedchem.6c00399 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 03.10.2026. Verfasst von Nakita Reddy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Catalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban4001, South Africa. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, beta-Lactamase Inhibitors, beta-Lactamases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation, South African Medical Research Council, Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
The silent pandemic of antimicrobial resistance (AMR) continues to drive global morbidity and mortality. Resistance is often mediated by co-expression of serine β-lactamases (SBLs) and metallo-β-lactamases (MBLs), limiting treatment options. While several SBL inhibitors are clinically available, MBL inhibitors are yet to reach the market, and only a few candidates are in late-stage development. Dual-β-lactamase inhibitors remain an unmet goal. To preserve existing antibiotics, alternative strategies are required. This perspective highlights triple combination therapy comprising a β-lactam antibiotic, an SBL inhibitor, and an MBL-targeting agent to achieve broader coverage. Notably, in 2025, the U.S Food and Drug Administration (FDA) has approved aztreonam−avibactam (Emblaveo), in combination with metronidazole, for adults with complicated intra-abdominal infections who have limited or no alternative treatment options. Expanding such strategies may help mitigate AMR and support ongoing antimicrobial development efforts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Catalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban4001, South Africa.
- Office of AIDS and TB, South African Medical Research Council, Pretoria0084, South Africa.
- Laboratory of Computer Modeling of Molecular Biosystems, Federal University of Pará, Belém66075-110, Brazil.
- Science for Life Laboratory, Drug Discovery & Development Platform & Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm17177, Swe…
- Ansynth Laboratories PTY LTD, 498 Grove End Drive, Durban4068, South Africa.
ORCID-Profile: Nakita Reddy, José Rogério A Silva, Per I Arvidsson, Hendrik G Kruger, Thavendran Govender, Tricia Naicker
Förderung
- National Research Foundation
- South African Medical Research Council
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Reddy, N., Silva, J. R. A., Arvidsson, P. I., Kruger, H. G., Govender, T., & Naicker, T. (2026). Triple Combination Therapy: A Promising Path Forward against β-Lactamase-Mediated Resistance. Journal of Medicinal Chemistry, 69(20), 23075-23091. https://doi.org/10.1021/acs.jmedchem.6c00399
Vancouver
Reddy N, Silva JRA, Arvidsson PI, Kruger HG, Govender T, Naicker T. Triple Combination Therapy: A Promising Path Forward against β-Lactamase-Mediated Resistance. Journal of Medicinal Chemistry. 2026;69(20):23075-23091. doi:10.1021/acs.jmedchem.6c00399
BibTeX
@article{Reddy2026,
author = {Reddy, Nakita and Silva, José Rogério A and Arvidsson, Per I and Kruger, Hendrik G and Govender, Thavendran and Naicker, Tricia},
title = {Triple Combination Therapy: A Promising Path Forward against β-Lactamase-Mediated Resistance},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {20},
pages = {23075--23091},
doi = {10.1021/acs.jmedchem.6c00399}
}
EUVIMED